VivoSeq
Other

Amenorrhea

18

Pipeline Programs↗

4

Active Trials↗

8

Companies Involved↗

Amenorrhea is an emerging landscape with 18 programs across 8 companies. The most active players are Regeneron, Stephanie B. Seminara, MD, Chiesi Farmaceutici S.p.A.. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

63/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

1 program

Phase 2S

Stephanie B. Seminara, MD

1 program

Phase 2Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

1 program

Phase 2Ferring logo

Ferring

1 program

Phase 3Amgen logo

Amgen

1 program

Phase 3Pfizer logo

Pfizer

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

15 of 17 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody212%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 95% of 20 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed5 · 36%
Recruiting3 · 21%
Terminated2 · 14%
Unknown status2 · 14%
Withdrawn1 · 7%
Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea
Recruiting·MMassachusetts General Hospital·Phase 3·NCT06533865·114 enrolled
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
Recruiting·Regeneron logoRegeneron·Phase 2·NCT07235917·34 enrolled
Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
Recruiting·SStephanie B. Seminara, MD·Phase 2·NCT07224438·20 enrolled
Menstrual Cycle Maintenance and Quality of Life: A Prospective Study
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT00589654·810 enrolled
Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients
Completed·—·Phase 4·NCT01206153·84 enrolled
Impact of Oropharyngeal Administration of Colostrum in the First 48 Hours of Life Term Premature Newborn ≤ 32 Weeks of Amenorrhea
Completed·—·N/A·NCT02650167·140 enrolled
Study of Leptin for the Treatment of Hypothalamic Amenorrhea
Completed·—·Phase 2·NCT00130117·20 enrolled
A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea
Completed·DDuramed Research·Phase 2·NCT00196391·180 enrolled
Treatment of Menstrual Cycle Alterations in Adolescents
Completed·LLo.Li.Pharma s.r.l·Preclinical·NCT06800170·41 enrolled
The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates
Terminated·—·Phase 3·NCT02449161·60 enrolled
A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea
Terminated·TTherapeuticsMD·Phase 3·NCT02019589·6 enrolled
Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea
Withdrawn·—·N/A·NCT01423487
Prostaglandins Use Before Mirena IUD Insertion in Prev CS Women During Lactational Amenorrhea
Unknown status·—·N/A·NCT04646161·400 enrolled
Total Antioxidant Capacity Before and After HRT in Hypotalamic Amenorrhea
Unknown status·—·N/A·NCT02984696·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)